Clene (CLNN) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Oncology (CTOR) has outperformed Clene (CLNN) over the past year, losing 55.4% versus a loss of 62.0%. Citius Oncology is the larger company by market cap ($53.2 million vs $50.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | CTOR |
|---|---|---|
| Share price | $3.52 | $0.5035 |
| Market cap | $50.69M | $53.25M |
| 1-day change | +0.57% | -10.95% |
| YTD return | -40.03% | -49.65% |
| 1-year return | -62.03% | -55.44% |
| 5-year return | -96.28% | — |
| EPS (TTM) | $-2.30 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $200.00K | — |
| Revenue growth (YoY) | -41.52% | — |
| Net income (latest FY) | $-26.17M | $-24.76M |
| Gross margin | 78.50% | — |
| Operating margin | -11541.50% | — |
| Net margin | -13086.50% | — |
| 52-week high | $10.84 | $1.83 |
| 52-week low | $3.02 | $0.491 |
| Distance from 52-week high | -67.53% | -72.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +814.77% | +694.44% |
| Average volume | 115.06K | 114.02K |
| Shares outstanding | 14.40M | 105.76M |
| Employees | 76 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
CLNN vs CTOR FAQ
Which is bigger, Clene or Citius Oncology?
Citius Oncology (CTOR) is larger, with a market capitalization of $53.25M compared with $50.69M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or CTOR?
CTOR returned -55.44% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Citius Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.